4Jiang Q, Xu LP, Liu DH, et al. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic- phase chronic myelogenous Ieukcmia[J]. Leukemia, 2013, 27( 12):2410-2413.
5Deininger M, 0' Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML- CP) treated with imatinib [J]. Blood (ASH Annual Meeting Abstracts), 2009, 114: Abstract 1126.
6Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV[J]. Leukemia, 2015, 29(5) :1123- 1132.
7NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Chronic Myelogenous Leukemia [S/OLJ. Version 1.2015 [2014- 08- 28]. http://www.nccn.org/professionals/physician_gls/ Cguidelines.asp.
8Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013[J]. Blood, 2013,122(6):872-884.
9Hughes TP, SagJio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib[J]. Blood, 2014,123(9):1353-1360.
10Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3- year follow- up from a randomized phase 3 trial (DASISION) [J]. Blood, 2014,123(4):494-500.
